| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.4034 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.4034 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.4034 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.4034 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.4034 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.4034 | scaled units | Placebo | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.4292 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.4396 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.4410 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.4508 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.4542 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.4735 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.4796 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.4801 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.4953 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.4984 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.5243 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.5718 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.5803 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.5833 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.6185 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.6224 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.6252 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.6273 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.6362 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.6388 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.6427 | scaled units | Placebo | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.6529 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.6619 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.6624 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.6695 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.6699 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.6736 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.6791 | scaled units | Placebo | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.6951 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.7003 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.7048 | scaled units | Placebo | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.7156 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.7177 | scaled units | Placebo | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.7241 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.7266 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.7308 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.7324 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.7450 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.7496 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.7718 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.7786 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.7806 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.7816 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.7831 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.7858 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.7907 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.7925 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.8121 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.8189 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.8199 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.8248 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.8470 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.8489 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.8506 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.8533 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.8726 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.8732 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.8755 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.8760 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.8807 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.8840 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.8888 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.8924 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9002 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9010 | scaled units | Placebo | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9029 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9104 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9163 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9210 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9217 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9246 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9285 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9323 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9329 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9414 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9590 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9598 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9635 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9650 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9693 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9767 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9774 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9779 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9798 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9828 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9839 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9907 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9917 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 0.9975 | scaled units | Placebo | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0000 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0025 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0083 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0179 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0331 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0373 | scaled units | Low-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0437 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0578 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0579 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0589 | scaled units | High-Dose | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0613 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0630 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0663 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0708 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0782 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0823 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0826 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0917 | scaled units | Placebo | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.0954 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.1020 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.1037 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.1115 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.1202 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.1206 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.1303 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.1384 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.1435 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.1516 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.1581 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.1599 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.1602 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.1693 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.1788 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.1802 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.1852 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.1857 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.1878 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.2030 | scaled units | Placebo | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.2054 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.2119 | scaled units | Placebo | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.2122 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.2134 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.2255 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.2286 | scaled units | Low-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.2379 | scaled units | High-Dose | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.2498 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.2531 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.2757 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.2902 | scaled units | Placebo | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.2907 | scaled units | Placebo | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.3043 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.3066 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.3070 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.3106 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.3183 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.3412 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.3464 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.3478 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.3811 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.3984 | scaled units | Low-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.4375 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.4415 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.4418 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.4487 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.4511 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.4733 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.4737 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.4953 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.5244 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.5284 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.5834 | scaled units | Placebo | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.5876 | scaled units | Low-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.5901 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.6006 | scaled units | Placebo | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.6319 | scaled units | Placebo | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.6497 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.6715 | scaled units | Placebo | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.7057 | scaled units | High-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.7066 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.7079 | scaled units | High-Dose | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.7182 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.7424 | scaled units | High-Dose | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.7817 | scaled units | High-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.8135 | scaled units | Placebo | +23HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.8303 | scaled units | Placebo | -0.5HR |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.9479 | scaled units | Low-Dose | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 1.9785 | scaled units | Placebo | BASELINE |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 2.1521 | scaled units | Low-Dose | +71HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 2.1762 | scaled units | Placebo | +47HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 4.6113 | scaled units | Placebo | +4HR POST INFUSION |
| HILIC NEGATIVE ION MODE | azelate (nonanedioate; C9) | 5.5895 | scaled units | Placebo | +4HR POST INFUSION |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|